Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Aug;56(8):4478-82.
doi: 10.1128/AAC.00194-12. Epub 2012 May 14.

In vitro activities of LTX-109, a synthetic antimicrobial peptide, against methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, daptomycin-nonsusceptible, and linezolid-nonsusceptible Staphylococcus aureus

Louis D Saravolatz  1 , Joan Pawlak, Leonard Johnson, Hector Bonilla, Louis D Saravolatz 2nd, Mohamad G Fakih, Anders Fugelli, Wenche Marie Olsen
Affiliations

In vitro activities of LTX-109, a synthetic antimicrobial peptide, against methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, daptomycin-nonsusceptible, and linezolid-nonsusceptible Staphylococcus aureus

Louis D Saravolatz et al. Antimicrob Agents Chemother. 2012 Aug.

Abstract

LTX-109 and eight other antimicrobial agents were evaluated against 155 methicillin-resistant Staphylococcus aureus (MRSA) isolates, including strains resistant to vancomycin and strains with decreased susceptibility to daptomycin and linezolid, by microdilution tests to determine MICs. Time-kill assays were performed against representative MRSA, vancomycin-intermediate S. aureus (VISA), and vancomycin-resistant S. aureus (VRSA) isolates. LTX-109 demonstrated a MIC range of 2 to 4 μg/ml and dose-dependent rapid bactericidal activity against S. aureus. This activity was not influenced by resistance to other antistaphylococcal agents.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Babu T, Rekasius V, Parada JP, Schreckenberger P, Challapalli M. 2009. Mupirocin resistance among methicillin-resistant Staphylococcus aureus-colonized patients admission to a tertiary care medical center. J. Clin. Microbiol. 47:2279–2280 - PMC - PubMed
    1. Clinical and Laboratory Standards Institute 1999. Methods for determining bactericidal activity of antimicrobial agents; approved guidelines. M26-A Clinical and Laboratory Standards Institute, Wayne, PA
    1. Clinical and Laboratory Standards Institute 2008. Performance standards for antimicrobial susceptibility testing, 18th informational supplement M100-S18. Clinical and Laboratory Standards Institute, Wayne, PA
    1. Goossens H, Ferech M, Vander Stichele R, Elseviers M. 2005. Outpatient antibiotic use in Europe and association with resistance: a cross-national database study. Lancet 365:579–587 - PubMed
    1. Haug BE, Stensen W, Kalaaji M, Rekdal O, Svendsen JS. 2008. Synthetic antimicrobial peptidomimetics with therapeutic potential. J. Med. Chem. 51:4306–4314 - PubMed

MeSH terms